Country for PR: United States
Contributor: PR Newswire New York
Wednesday, March 07 2018 - 14:21
4C Medical's Transcatheter Mitral Valve Technology Receives First Place in Cardiovascular Research Technologies 2018 Competition
BROOKLYN PARK, Minn., March 7, 2018 /PRNewswire-AsiaNet/ --

4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive 
technologies for structural heart disease, today announced that AltaValve(TM), 
its medical device for mitral regurgitation (MR), was awarded first place in 
the Cardiovascular Research Technologies (CRT) competition held March 3-6, 2018 
in Washington, DC. 

Logo -

"AltaValve will answer a real unmet clinical need," said Philippe Genereux, MD, 
Co-Director of the Structural Heart Program at the Gagnon Cardiovascular 
Institute of Morristown Medical Center (Morristown, NJ) and a practicing 
Interventional Cardiologist at Hopital du Sacre-Coeur de Montreal (Montreal, 
Canada). "Delivered transseptally, this device will provide a treatment option 
for a broad MR patient population. This includes patients that can be treated 
by other transcatheter mitral valve replacement (TMVR) devices, patients that 
cannot be treated by other TMVR devices, and even patients with previously 
failed mitral repair." 

Dr. Genereux highlighted AltaValve in the presentation titled "A Novel 
Transcatheter MR Treatment Technology" which was part of the CRT Cardiovascular 
Innovations session.

"Despite the fact that the TMVR market is crowded with many devices trying to 
fit into the irregular and dynamic native mitral valve annulus, AltaValve is 
the only device that is truly differentiated – with supra-annular positioning 
and atrial-only fixation – and agnostic to the etiology of mitral 
regurgitation," said Jeffrey Chambers, MD, Founder and Chief Medical Officer of 
4C Medical and Director of the Cardiac Catheterization Lab at Metropolitan 
Heart and Vascular Institute in Minneapolis, MN. 

At the CRT meeting, Dr. Chambers presented "4C Solutions that Preserve the 
Native Mitral Valve" in the Pulmonic, Tricuspid & Mitral Innovations session.

Designed to eliminate the known issues of current TMVR technologies, AltaValve 
is positioned supra annular to the native mitral valve, and its atrial-only 
placement ensures that critical cardiac structures within the left ventricle, 
including the chordae tendineae and the left ventricular outflow tract, are 
preserved. Moreover, AltaValve avoids issues related to the complexity and 
variability of the mitral annulus, making the device suitable for a broader 
patient population.

"The uniqueness of the device concept combined with our exceptional and unified 
team continue to lead to tremendous progress," said Robert Thatcher, CEO of 4C 
Medical. "This award is a testament to our continued momentum toward the 
ultimate goal of delivering new treatment options to patients who may not have 
options today."

About 4C Medical Technologies, Inc. 
4C Medical is a medical device company developing minimally invasive 
technologies for structural heart disease, focusing initially on mitral 
regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. 
The company's AltaValve is the first MR treatment with supra-annular 
positioning and atrial-only fixation. It preserves the native mitral valve and 
left ventricle, eliminating known issues associated with transcatheter mitral 
valve replacement technologies which rely on placement and fixation in the 
native mitral annulus and left ventricle. 

Media Contacts 
Robert Thatcher 
Chief Executive Officer 

Jim Flaherty 
Chief Financial Officer 

SOURCE:  4C Medical Technologies, Inc.